

Level 2, 66 Hunter Street
Sydney NSW 2000
Tel: (61-2) 9300 3344
Fax: (61-2) 9221 6333
E-mail: pnightingale@biotron.com.au
Website: www.biotron.com.au

9 June 2017

The Manager Companies
ASX Limited
20 Bridge Street
Sydney NSW 2000

(2 pages by email)

Dear Madam

**LYNX FINANCIAL APPOINTED AS CORPORATE ADVISOR
TO ADVANCE COMMERCIALISATION STRATEGY IN CHINA**

Sydney, Australia, 9 June 2017 – Biotron Limited (ASX:BIT, Biotron or Company) is pleased to announce the appointment of leading Shanghai based advisory group, Lynx Financial (HK) Ltd (Lynx Financial) as corporate advisor to assist the Company with the execution of its China commercialisation strategy.

Lynx Financial will support Biotron in identifying and negotiating with suitable partners to enable the licensing of the Company's antiviral drug platform in the People's Republic of China. Lynx Financial has a strong focus on China's rapidly growing healthcare sector and a particular strength in cross boarder transactions, facilitated by offices in Shanghai, San Diego and Tel Aviv.

Biotron's Managing Director, Dr Michelle Miller noted "The Company believes there is a significant opportunity to execute a regional licensing agreement for its antiviral drug platform in China. Respiratory and emerging viruses are an issue in China as in the rest of the world, and Hepatitis C virus (HCV) remains a significant problem in the region."

Managing Director of Lynx Financial, Mr Donald Xu said "We are very excited to be working with Biotron; China is now the second largest pharmaceutical market in the world and growing at a significant rate. We believe Biotron's antiviral platform represents a strong regional partnering opportunity here in China and we look forward to assisting the company in executing its China strategy".

Yours sincerely



Peter J. Nightingale
Company Secretary

pjn8945

About Biotron

Biotron Limited is engaged in the research, development, and commercialisation of drugs targeting significant viral diseases with unmet medical need. The Company has BIT225 in clinical development for both HIV-1 and HCV and also has several earlier stage preclinical and research programs designing drugs that target a class of virus protein known as viroporins which have a key role in the virus life cycle of a very broad range of viruses, many of which have caused worldwide health issues such as Dengue, Hepatitis B, Ebola, Middle East Respiratory virus, Influenza and Zika viruses.

Enquiries

Dr Michelle Miller
Managing Director
Biotron Limited
+61-2 9805 0488
+61-(0)412313329

Rudi Michelson
Monsoon Communications
+61-3 9620 3333